Abstract: Objective To analyze the efficacy of sacubitril valsartan in the treatment of elderly patients with chronic heart failure and the influence on the heart function, serum levels of cardiotrophin-1(CT-1) and β-endorphin(β-EP). Methods A total of 100 patients with chronic heart failure in our hospital from April 2019 to June 2020 were randomly divided into the observation group and the control group,with 50 cases in each group. The control group was treated with conventional treatment, and the observation group was given sacubitril valsartan sodium tablets on the basis of the control group. The curative effect of the two groups was observed and evaluated. The heart function indexes, 6-minute walking distance (6MWD), Minnesota Living with Heart Failure Questionaire (MLHFQ) score, the serum levels of CT-1 and β-EP before and after the treatment were detected and compared. Results The clinical effective rate of the observation group was significantly higher than that of the control group (94.0% vs 74.0%, P<0.05). After treatment, the levels of left ventricular ejection fraction (LVEF), stroke volume (SV), 6MWD and CT-1 were significantly higher and the levels of left ventricular end-diastolic dimension (LVEDD),β-EP score and MLHFQ score were significantly lower in two groups than those before treatment, especially in the observation group (P<0.01). Conclusions Sacubitril valsartan can effectively improve the clinical efficacy, cardiac function and serum levels of CT-1 and β -EP of the elderly patients with chronic heart failure.

Key words: sacubatro valsartan, chronic heart failure, cardiac function, cardiotrophin-1, β-endorphin